Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis Meeting Abstract
| Authors: | Cho, B. C.; Ahn, M. J.; Baik, C.; Garcia, R.; Goldman, J. W.; Kim, S. W.; Lee, J. S.; Nishio, M.; Ponce, S.; Salgia, R.; Teraoka, S.; Yoshida, T.; Yu, H. A.; Ambrose, H.; Cosaert, J.; Hartmaier, R.; Maidment, J.; Pluta, M.; Okamoto, I. |
| Abstract Title: | Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis |
| Meeting Title: | European Lung Cancer Congress (ELCC) 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Mar 30-Apr 2 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-04-01 |
| Start Page: | S34 |
| End Page: | S35 |
| Language: | English |
| ACCESSION: | WOS:000778453100014 |
| DOI: | 10.1016/j.annonc.2022.02.022 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 13P -- Source: Wos |
